Clinical Trial Update: A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating Ifinatamab Deruxtecan, as monotherapy or in combination, for metastatic castration-resistant prostate cancer (mCRPC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Ifinatamab Deruxtecan (Ifinatamab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Castration-Resistant Prostatic Cancer, Metastasis | Phase 1, Phase 2 | Status: RECRUITING